SEATTLE — Initial experience with two ranibizumab biosimilars showed no unexpected adverse events, according to a study presented at the American Society of Retina Specialists annual meeting.
Carl C. Awh, MD, FASRS, said there are now two FDA-approved ranibizumab biosimilars, Byooviz (ranibizumab-nuna, Samsung Bioepis/Biogen) and Cimerli (ranibizumab-eqrn, Coherus BioSciences), after the patent for Lucentis (ranibizumab, Genentech) expired in 2020. However, the biosimilars were supported by relatively small clinical studies.
“Are there any unanticipated clinical outcomes associated